Endothelin Receptor Antagonist

Phase 3Small molecule

RRadboud University Medical Center

Endothelin Receptor Antagonist is one of 50 small molecule programs targeting Efficacy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyEnrolling by invitation

Coronary Microvascular Dysfunction (CMD)Active, not recruiting

EfficacyPhase 3

Enrolling by invitation

Coronary Microvascular Dysfunction (CMD)Preclinical

Active, not recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Vabysmo

Roche

Phase 3

2 3

Rayos

RRoxane Laboratories

Phase 3

5 4

Paraplatin

AAvyxa

Phase 3

4 5

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

1 6

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

1 7

Levocept

SSebela Women's Health Inc.

Phase 3

1 8

Veracept

SSebela Women's Health Inc.

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy1 trial

Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

Enrolling by invitation·RRadboud University Medical Center·Phase 2/3·NCT06432452·100 enrolled

Coronary Microvascular Dysfunction (CMD)1 trial

Determining the Role of Endothelin in Microcirculatory Function in Myocardial Ischaemia

Active, not recruiting·LLiverpool University Hospitals NHS Foundation Trust·Preclinical·NCT07670091·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Endothelin Receptor Antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Endothelin Receptor Antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Endothelin Receptor Antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRadboud University Medical Center

Endothelin Receptor Antagonist

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy1 trial

Coronary Microvascular Dysfunction (CMD)1 trial

References

Drug Info

Quick Facts

Related News